Evidence map›Paper›PMID 27121353›Full record

ArticleInternational journal of cancer2016

Variant-specific persistence of infections with human papillomavirus Types 31, 33, 45, 56 and 58 and risk of cervical intraepithelial neoplasia.

Long Fu Xi, Mark Schiffman, Laura A Koutsky, James P Hughes, Ayaka Hulbert, Zhenping Shen, Denise A Galloway, Nancy B Kiviat

Abstract read
In one paragraph

Article in International journal of cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Long Fu XiDepartment of Pathology, School of Medicine, University of Washington, Seattle, WA.
Mark SchiffmanDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD.
Laura A KoutskyDepartment of Epidemiology, School of Public Health and Community Medicine, University of Washington, Seattle, WA.
James P HughesDepartment of Biostatistics, School of Public Health and Community Medicine, University of Washington, Seattle, WA.
Ayaka HulbertDepartment of Pathology, School of Medicine, University of Washington, Seattle, WA.
Zhenping ShenDepartment of Pathology, School of Medicine, University of Washington, Seattle, WA.
Denise A GallowayDivision of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA.
Nancy B KiviatDepartment of Pathology, School of Medicine, University of Washington, Seattle, WA.
University of Washington · USFred Hutch Cancer Center · USNational Cancer Institute · US

Funding

Intratypic variation of oncogenic HPV types as a risk factor for cervical neoplasR01CA133569 · NCI · UNIVERSITY OF WASHINGTON · PI XI, LONG FU · 2009 to 2012
$1.7M
NCI NIH HHS R01 CA133569
6 · The paper itself

Abstract

In our previous study of the etiologic role of oncogenic human papillomavirus (HPV) types other than HPV16 and 18, we observed a significantly higher risk of cervical intraepithelial neoplasia Grades 2-3 (CIN2/3) associated with certain lineages of HPV types 31/33/45/56/58 [called high-risk (HR) variants] compared with non-HR variants. This study was to examine whether these intra-type variants differ in persistence of the infection and persistence-associated risk of CIN2/3. Study subjects were women who had any of HPV types 31/33/45/56/58 newly detected during a 2-year follow-up with 6-month intervals. For each type, the first positive sample was used for variant characterization. The association of reverting-to-negativity with group of the variants and CIN2/3 with length of positivity was assessed using discrete Cox regression and logistic regression, respectively. Of the 598 newly detected, type-specific HPV infections, 312 became undetectable during follow-up. Infections with HR, compared with non-HR, variants were marginally more likely to become negative [adjusted hazard ratio = 1.3; 95% confidence interval (CI), 0.9-1.8]. The adjusted odds ratio associating with the development of CIN2/3 was 3.0 (95% CI, 1.2-7.4) for persistent infections with HR variants for 6 months and 10.0 (95% CI, 3.8-38.0) for persistent infections with HR variants for 12-18 months as compared with the first positive detection of HR variants. Among women with non-HR variants, there were no appreciable differences in risk of CIN2/3 by length of positivity. Findings suggest that the lineage-associated risk of CIN2/3 was not mediated through a prolonged persistent infection, but oncogenic heterogeneity of the variants.

Indexed as

PapillomaviridaeFollow-Up StudiesHumansKaplan-Meier EstimateNeoplasm GradingPapillomavirus InfectionsProportional Hazards ModelsRandomized Controlled Trials as TopicUterine Cervical Dysplasiacervical intraepithelial neoplasiahuman papillomaviruspersistencevariants

Identifiers

PMID27121353
PMCPMC4911294
OpenAlexW2344794020

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.